In April 2025, according to an article published by the Heart Rhythm Society, a recent clinical study, TRANSFORM-AF, found that GLP-1 receptor agonists (GLP-1 RAs), typically used for diabetes, may reduce atrial fibrillation (AF)-related events in patients with both obesity and AF
Cunto duran los efectos secundarios de la semaglutida
The content on this blog is provided as is and no representations are made that the content is error-free
Cardiovascular Function: DPP-4 is present on the endothelial cells [5], [9]
Studies show spirulina actively binds to heavy metals including arsenic, cadmium, and lead in the body, protecting organs from damage
A central insight emerging from the GLP-1 experience is that biological pleiotropy does not preclude therapeutic utility